<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available. CSPC Pharmaceutical Group has published an updated list of its board of directors, detailing the roles of executive directors, including the chairman, vice-chairmen, and senior management, alongside its independent non-executive directors. The company also clarified the composition and leadership of its audit, nomination, and remuneration committees, signaling a structured corporate governance framework that may enhance oversight and transparency for shareholders. The disclosure underscores the balance between management and independent oversight on the board, with independent directors taking key positions on core committees. This governance setup is likely intended to strengthen risk control, regulatory compliance, and investor confidence as CSPC continues to operate in the highly regulated pharmaceutical sector. The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page. More about CSPC Pharmaceutical Group CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed under stock code 1093. It operates in the healthcare and drug manufacturing industry, with a governance structure comprising executive directors overseeing operations and independent non-executive directors providing oversight through key board committees. YTD Price Performance: 17.44% Average Trading Volume: 122,129,057 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$113.9B For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.</div>

159892

513700

520880

CSPC Pharmaceutical Group has updated its board of directors, detailing roles of executive and independent non-executive directors, and clarifying the composition of its audit, nomination, and remuneration committees. This governance structure aims to enhance oversight and transparency, strengthening risk control and investor confidence in the regulated pharmaceutical sector. The latest analyst rating for CSPC stock (HK:1093) is a Hold with a price target of HK$10.70. The company has a market cap of HK$113.9B and a year-to-date price performance of 17.44%.

Tip Ranks

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

CSPC PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

CSPC Pharmaceutical Updates Board Composition and Committee Roles